Topica
Founded Year
1998Stage
Series C | DeadTotal Raised
$44.5MLast Raised
$28MAbout Topica
Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.
Loading...
Loading...
Topica Patents
Topica has filed 1 patent.
The 3 most popular patent topics include:
- internet television
- teleconferencing
- video codecs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/24/2019 | Videotelephony, Teleconferencing, Video codecs, Web conferencing, Internet television | Application |
Application Date | 6/24/2019 |
|---|---|
Grant Date | |
Title | |
Related Topics | Videotelephony, Teleconferencing, Video codecs, Web conferencing, Internet television |
Status | Application |
Latest Topica News
Aug 24, 2023
This web version of the DATA VANTAGE twice-weekly premium newsletter is available only to our premium subscribers. Unlock access by picking up any of our premium subscription plans .
Topica Frequently Asked Questions (FAQ)
When was Topica founded?
Topica was founded in 1998.
Where is Topica's headquarters?
Topica's headquarters is located at 1 Post Street, San Francisco.
What is Topica's latest funding round?
Topica's latest funding round is Series C.
How much did Topica raise?
Topica raised a total of $44.5M.
Who are the investors of Topica?
Investors of Topica include Highland Capital Partners, August Capital, Moore Capital Management, Draper Richards, Morgan Stanley and 4 more.
Who are Topica's competitors?
Competitors of Topica include OyaGen, Tobira Therapeutics, Anacor Pharmaceuticals, InterMune, Trius Therapeutics and 7 more.
Loading...
Compare Topica to Competitors
OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.
Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.
Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology
PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.
Azides Pharmaceuticals, Inc is a developer of HIV drugs to treat viral strains resistant to existing medications such as azidothymidine, or AZT,
Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.
Loading...